189 related articles for article (PubMed ID: 23553421)
41. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
[TBL] [Abstract][Full Text] [Related]
42. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors.
Kesler KA; Rieger KM; Hammoud ZT; Kruter LE; Perkins SM; Turrentine MW; Schneider BP; Einhorn LH; Brown JW
Ann Thorac Surg; 2008 Feb; 85(2):371-8. PubMed ID: 18222228
[TBL] [Abstract][Full Text] [Related]
43. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
[TBL] [Abstract][Full Text] [Related]
44. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.
Nishikawa M; Miyake H; Fujisawa M
Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313
[TBL] [Abstract][Full Text] [Related]
45. Is high-dose chemotherapy after primary chemotherapy a therapeutic option for patients with primary mediastinal nonseminomatous germ cell tumor?
Banna GL; De Giorgi U; Ferrari B; Castagna L; Alloisio M; Marangolo M; Rosti G; Santoro A
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1085-91. PubMed ID: 17084372
[TBL] [Abstract][Full Text] [Related]
46. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin-based chemotherapy followed by surgery for malignant nonseminomatous germ cell tumor of mediastinum: one institution's experience.
Nakamura Y; Matsumura A; Katsura H; Sakaguchi M; Ito N; Kitahara N; Ose N; Kitaichi M
Gen Thorac Cardiovasc Surg; 2009 Jul; 57(7):363-8. PubMed ID: 19597926
[TBL] [Abstract][Full Text] [Related]
48. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
49. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience.
Rodney AJ; Tannir NM; Siefker-Radtke AO; Liu P; Walsh GL; Millikan RE; Swisher SG; Tu SM; Pagliaro LC
Urol Oncol; 2012; 30(6):879-85. PubMed ID: 20933444
[TBL] [Abstract][Full Text] [Related]
50. Giant mediastinal germ cell tumor.
Traibi A; Bakkali YE; Hammoumi ME; Kabiri el H
Intern Med; 2011; 50(11):1261-2. PubMed ID: 21628948
[No Abstract] [Full Text] [Related]
51. Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.
Pectasides D; Pectasides E; Papaxoinis G; Xiros N; Kamposioras K; Tountas N; Economopoulos T
Urol Oncol; 2010; 28(6):617-23. PubMed ID: 19110454
[TBL] [Abstract][Full Text] [Related]
52. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.
Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O;
Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861
[TBL] [Abstract][Full Text] [Related]
53. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
54. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
55. High dose chemotherapy in germ cell tumors.
Rosti G; De Giorgi U
Tunis Med; 2005 Dec; 83 Suppl 12():85-6. PubMed ID: 16430076
[No Abstract] [Full Text] [Related]
56. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
Bokemeyer C; Schleucher N; Metzner B; Thomas M; Rick O; Schmoll HJ; Kollmannsberger C; Boehlke I; Kanz L; Hartmann JT
Br J Cancer; 2003 Jul; 89(1):29-35. PubMed ID: 12838296
[TBL] [Abstract][Full Text] [Related]
57. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience.
Adra N; Abonour R; Althouse SK; Albany C; Hanna NH; Einhorn LH
J Clin Oncol; 2017 Apr; 35(10):1096-1102. PubMed ID: 27870561
[TBL] [Abstract][Full Text] [Related]
58. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
59. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Faure-Conter C; Orbach D; Cropet C; Baranzelli MC; Martelli H; Thebaud E; Vérité C; Rome A; Fasola S; Corradini N; Rocourt N; Frappaz D; Kalfa N; Patte C
Pediatr Blood Cancer; 2014 Feb; 61(2):253-9. PubMed ID: 23940114
[TBL] [Abstract][Full Text] [Related]
60. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
